NCT01427101

Brief Summary

The aim of this study was to compare debulking surgery and cytoreductive surgery in patients with Pseudomyxoma Peritonei with respect to efficacy and safety.

Trial Health

50
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 1993

Completed
18 years until next milestone

First Submitted

Initial submission to the registry

August 31, 2011

Completed
1 day until next milestone

First Posted

Study publicly available on registry

September 1, 2011

Completed
Last Updated

September 1, 2011

Status Verified

August 1, 2011

First QC Date

August 31, 2011

Last Update Submit

August 31, 2011

Conditions

Pseudomyxoma Peritonei

Keywords

Pseudomyxoma PeritoneiCytoreductive surgeryDebulking surgeryIntraperitoneal chemotherapy

Outcome Measures

Primary Outcomes (1)

  • Overall survival

    from treatment and forward

Secondary Outcomes (1)

  • morbidity and mortality

    90 days

Eligibility Criteria

Age20 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients with Pseudomyxoma Peritonei, sceduled for surgical treatment at Uppsala University Hospital.

You may qualify if:

  • Patients with radiology histopathology finding of Pseudomyxoma Peritonei

You may not qualify if:

  • Preformance status WHO \>2 and histopathology shows other origin then Pseudomyxoma Peritonei

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Biospecimen

Patients treated from 1993 are included and during these years treatment strategy has changed. The different strategies are compared but its juts one cohort of patients. No completion date are set due to that reports from other centres show that there are longtime survivers in both treatment groups.

MeSH Terms

Conditions

Pseudomyxoma Peritonei

Condition Hierarchy (Ancestors)

Adenocarcinoma, MucinousAdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsNeoplasms, Cystic, Mucinous, and Serous

Study Officials

  • Haile Mahteme, MD, PhD

    Uppsala University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 31, 2011

First Posted

September 1, 2011

Study Start

September 1, 1993

Last Updated

September 1, 2011

Record last verified: 2011-08